about
Cardiorenal syndrome: the emerging role of protein-bound uremic toxinsInotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxinContribution of microRNA to pathological fibrosis in cardio-renal syndrome: impact of uremic toxinsCardiovascular role of urotensin II: effect of chronic infusion in the rat.Fibrosis as a therapeutic target post-myocardial infarction.Do p38 mitogen-activated protein kinase inhibitors have a future for the treatment of cardiovascular disease?Cardiorenal syndrome: pathophysiology, preclinical models, management and potential role of uraemic toxins.Early and delayed tranilast treatment reduces pathological fibrosis following myocardial infarction.Structural requirements for the interaction of sheep insulin-like factor 3 with relaxin receptors in rat atria.Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy.Attenuation of microglial and neuronal activation in the brain by ICV minocycline following myocardial infarction.Effect of urotensin II on skin microvessel tone in diabetic patients without heart failure or essential hypertension.Effect of atorvastatin on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction.Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial.Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction.Beta-adrenoceptor regulation and functional responses in the guinea-pig following chronic administration of the long-acting beta 2-adrenoceptor agonist formoterol.Chronic kidney disease with comorbid cardiac dysfunction exacerbates cardiac and renal damage.Beta-adrenoceptor subtypes and their desensitization mechanisms.Microglia activation in the hypothalamic PVN following myocardial infarction.Sustained activation of microglia in the hypothalamic PVN following myocardial infarction.Inhibition of Apoptosis Signal-Regulating Kinase 1 Attenuates Myocyte Hypertrophy and Fibroblast Collagen Synthesis.FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy.Cardiac tissue engineering in an in vivo vascularized chamber.Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.Localization of (-)-[125I]cyanopindolol binding in guinea-pig heart: characteristics of non-beta-adrenoceptor related binding in cardiac pacemaker and conducting regions.Protein kinases as cardiovascular therapeutic targets.Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats.Cardiomyocyte Functional Etiology in Heart Failure With Preserved Ejection Fraction Is Distinctive-A New Preclinical Model.A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarctionEffect of chemical sympathectomy on (-)-isoprenaline-induced changes in cardiac beta-adrenoceptor subtypes in the guinea-pig and ratDesensitization of cardiac beta-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteinsp38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the ratMyocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndromeAntagonists of organic anion transporters 1 and 3 ameliorate adverse cardiac remodelling induced by uremic toxin indoxyl sulfateSubtotal nephrectomy accelerates pathological cardiac remodeling post-myocardial infarction: implications for cardiorenal syndromeA practical guide to subtotal nephrectomy in the rat with subsequent methodology for assessing renal and cardiac functionCardiorenal Syndrome: Multi-organ Dysfunction Involving the Heart, Kidney and Vasculature
P50
Q26830674-BEF81587-91A4-4B26-8CC1-D1E62B7BD40FQ35044697-0536B86F-BB0E-484A-BFD9-FC1B8BAF76E3Q35588665-AB6D9951-AD3D-4785-ABE4-A0EDDD3DA160Q35914495-9276052A-2CB7-4827-8DB1-CDDC8A5D708AQ36051403-6FA9B9F0-25E3-400C-BF67-2948C9295668Q37329529-27C5F921-F343-464A-B891-68038392DA69Q37947677-BBCCC886-8F00-472A-930D-02FD97E98044Q43599637-08592C11-E76B-4419-874A-2F3CB070934FQ44237456-7A3C0F6F-374C-4602-9502-CC061DE72088Q44512781-684A5B29-C836-457D-8808-69F27E1E08B4Q44764031-17C4D207-DF3D-49CD-BB14-F4C355B0E855Q45274809-6B1D565A-FEB9-4BA9-8193-BE2548263CE4Q46036398-89494B97-FC07-4388-824F-637374E294D3Q46450248-A9A42F80-BF29-4A4C-B0D3-416697DE3345Q46775203-68A6F7C5-9860-4B25-994A-E8DE0E2CED65Q46842704-CED8EA3F-6E8C-41A4-AC0F-C5AB38D234EBQ47139510-5B9D8D0B-0A88-4A85-B373-926CB37ED236Q48018502-D9FF48AC-543B-4044-A314-B32F76F6951BQ48307377-232336DE-C777-4942-8E67-9941E6A48BDAQ48510093-674562BF-97F5-4F7B-A29B-6B11F3F7FF18Q49579319-89C7D123-3E4A-4ED4-9DDF-AF31F46C001EQ50515046-B68A37C2-D476-4203-B541-9DD2086C198EQ51089163-18AF77E0-55C3-4DF5-A9C4-BB82568BF885Q52653548-3432397F-866F-4B5F-B81D-23552F4B333EQ53848921-00E0715D-CCE2-4C7C-883B-66FB5B62AFCCQ54344570-6C927766-7851-4046-AC2B-03CE04BE63ACQ54704146-4331CEDD-ECE8-4233-8EE6-84B8C935D397Q55431118-9CF9DAD6-856E-48E4-80B1-4F4336BFD619Q63363145-DB9318B4-EDCB-4006-A62A-4FF8F07D6487Q72592013-D9400A6D-98CB-4528-9670-4A84F2628C3AQ77890681-4CE3004E-5C69-47C6-8D45-85EDFC630356Q80872153-CE624510-C510-4321-9367-3874FCE71D15Q83517612-772AA028-D569-4BBF-9260-3499F5C17E84Q84224137-41E1C369-4A10-43F2-AC73-F108E5CBC539Q85950693-513FDAD2-7FF9-4071-9FC4-2E9773DC0F6BQ87915010-7F1E3FF8-EB1E-48C5-BF4A-9525F360395DQ91588489-2DB11278-9D51-4CD4-8CDE-00CD0E1A4334
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andrew R Kompa
@ast
Andrew R Kompa
@en
Andrew R Kompa
@es
Andrew R Kompa
@nl
type
label
Andrew R Kompa
@ast
Andrew R Kompa
@en
Andrew R Kompa
@es
Andrew R Kompa
@nl
prefLabel
Andrew R Kompa
@ast
Andrew R Kompa
@en
Andrew R Kompa
@es
Andrew R Kompa
@nl
P106
P1153
6602566079
P31
P496
0000-0003-1002-2302